Dyne Therapeutics elects Brian Posner as Class III director

Dyne Therapeutics, Inc.

Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.
Posner deemed independent under Nasdaq rules; no committee appointments.
Received option to purchase 70,000 shares at $12.50 strike, vesting monthly over three years.
Annual cash compensation of $45,000 plus standard equity grants under director program.
No family relationships or transactions with company officers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.